Could a diabetes drug boost cancer immunotherapy? new trial tests the combo

NCT ID NCT04414540

First seen Jan 04, 2026 · Last updated Jun 02, 2026 · Updated 20 times

Summary

This study tests whether adding metformin (a common diabetes drug) to pembrolizumab (an immunotherapy) can help shrink tumors in people with advanced head and neck cancer that has spread. About 21 participants whose cancer cannot be cured with surgery or radiation will receive the combination. The goal is to see if the drugs work together to improve the immune system's ability to fight the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • University of Cincinnati Medical Center

    Cincinnati, Ohio, 45219, United States

Conditions

Explore the condition pages connected to this study.